You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Point of care immunoassay for rapid diagnosis of tinea capitis

    SBC: DxDiscovery Incorporated            Topic: NIBIB

    Tinea capitis scalp ringworm is a fungal dermatophyte infection of scalp hair follicles that afflicts of the U S pediatric population Tinea capitis is a major health care disparity because it occurs predominantly among individuals with a disadvantaged socioeconomic background and sub Saharan African descent Diagnosis of tinea capitis is currently dependent on culture and microscopy Both ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Point-of-care immunoassay for early diagnosis of pertussis

    SBC: DxDiscovery Incorporated            Topic: R

    Project Summary Pertussis is rapidly re emerging as a serious public health threat in the United StatesDespite high vaccine coverage nationallyannual reported cases in the U Shave been increasing recentlywith ayear high ofinMoreoverreported cases represent a large underestimate of pertussis infectionsDiagnosis of early pertussiscatarrhal stageprior to paroxysmal coughis particularly challenging be ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Non adjuvanted VLP Vaccine against Stealth H N Influenza

    SBC: EPIVAX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The avian origin H N influenza virus that emerged in humans in China in presents a unique challenge to vaccine development because it is poorly immunogenic Neutralizing antibodies are not detected in acute phase infection Anti H antibody responses are significantly delayed and exhibit low avidity in comparison with antibodies generated following seas ...

    SBIR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Multi Source E Beam kV X Ray Tube for Image Guided Radiotheraphy

    SBC: Telesecurity Sciences, Inc.            Topic: 102

    DESCRIPTION provided by applicant This project will develop a commercial product that will enable for the first time realtime tumor tracking during radiotherapy at an attractive price point and with minimal interference with standard clinical practice The key novel technology is an optimized multi source X ray tube with focal spots that is placed below the multi leaf collimator MLC of a r ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Advancing a Glioma Immunotherapy

    SBC: IN CYTU, INC.            Topic: 102

    DESCRIPTION provided by applicant A Phase II SBIR program of preclinical development is proposed for the development of an active specific immunotherapeutic called Cellariumandquot for treatment of glial cell based cancers Successful completion of this project will confirm therapeutic effect and pre clinical safety of the vaccine in preparation for first in human studies Upon demonstration of ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Biomarker discovery for immunodiagnosis of invasive candidiasis

    SBC: DxDiscovery Incorporated            Topic: NIAID

    DESCRIPTION (provided by applicant): Invasive candidiasis (IC) is one of the most serious threats to patients in a critical setting. With as many as 60,000 cases per year in the U.S., the total cost associated with IC in the U.S. may be as high as 2-4 billion/year. One of the most critical factors influencing patient outcome is early diagnosis. The goal of this project is a rapi and inexpensive i ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. An Automated Platform for High-throughput Network Electrophysiology

    SBC: Calista Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Calista Therapeutics has discovered a first-in-class, proprietary PDZ1-2 lead drug, AT010, that is being optimized and developed as an inhaled daily therapy for cystic fibrosis (CF). CF is a deadly inherited genetic disorder that disrupts chloride channel function, resulting in the buildup of sticky mucus in patient's lungs and other organs.CF patients hav ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Developing an Improved Electrocompetent E. coli Host

    SBC: Pro-Change Behavior Systems Inc            Topic: NCATS

    DESCRIPTION (provided by applicant): Chronic musculoskeletal pain creates a significant public health burden. Veterans are disproportionately affected by chronic musculoskeletal pain, and in particular, chronic low back pain (CLBP). The frequency and extent of co-occurrence of pain and PTSD, pain and Traumatic Brain Injury (TBI), and all three conditions (Post-deployment Multi-symptom Disorder (PM ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Expediting the Production of High Value, Standardized, and Transparent Data

    SBC: MJ Datacorp, Ltd.            Topic: NCATS

    DESCRIPTION (provided by applicant): Researchers and contractors are under increasing pressure to produce rapid turnaround times for data releases and publications. Inadequate data management is a common threat to good research and impedes the quick release of high value data. Despite its importance, many organizations do not have standardized data management practices that allow them to prepare h ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government